MedTrace Logo

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

NCT00883480 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2026-04-28

No results posted yet for this study

Summary

This is a pharmacogenic, prospective, and multicenter study in patients with advanced lung adenocarcinoma.

Conditions

Interventions

DRUG

Docetaxel

Docetaxel 75 mg/day 1 x 4 cycles

DRUG

Cisplatin

Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles

DRUG

Gemcitabine

Cisplatin 75 mg/ day 1 x 4 cycles Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles

DRUG

Erlotinib

Erlotinib 150 mg/day x 21 days

Sponsors & Collaborators

  • Spanish Lung Cancer Group

    lead OTHER

Principal Investigators

  • Rafael Rosell, MD · ICO-HOSPITAL GERMANS TRIAS I PUJOL

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2008-01-31
Completion
2008-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00883480 on ClinicalTrials.gov